28.06.2016 amp biosimilars AG  DE000A0SMU87

DGAP-News: amp biosimilars announces Klaus K. Wilgenbus as new CEO

DGAP-News: amp biosimilars AG / Key word(s): Change of Personnel amp biosimilars announces Klaus K. Wilgenbus as new CEO 28.06.2016 / 08:30 The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- amp biosimilars announces Klaus K. Wilgenbus as new CEO - Experienced industry executive to start as new CEO on July 1 - Founding CEO Marc W. Hentz steps down in a planned succession move Hamburg, Germany, June 28 2016 - amp biosimilars AG (ISIN: DE000A0SMU87), a company specializing in the development of high-quality biosimilars, today announced that Klaus K. Wilgenbus will lead the firm as the new CEO from July 1, 2016. In 2014 Klaus Wilgenbus retired as Corp. Senior VP Business Development Licensing and Strategy from Boehringer Ingelheim (BI). During his 18 year tenure at BI he held various positions covering Business Development, R&D, innovation management, corporate and commercial strategy, and organizational development. Under his leadership BI has entered into more than 200 strategic transactions incl. R&D collaborations, global co-promotion and co-marketing alliances, JV's and merger and acquisitions with business partners from North-America, EU and Asia. Klaus Wilgenbus also served on various boards such as Karolinska Development AB (Solna Sweden), Actimis Inc. (San Diego) and Boehringer Ingelheim Deutschland GmbH & Co KG and represented BI at the Board of (US) BIO. After 2014 Klaus Wilgenbus served as interim-CEO at Karolinska Development AB and advised as independent consultant small to mid sized biotech companies and life sciences investors in the areas of corporate strategy, fundraising and business transactions. Wilgenbus was trained as a physician in Germany and the US and holds an MD from RWTH Aachen. "It's an exciting time to be joining amp biosimilars, with the company's product and deal pipeline growing rapidly" said Wilgenbus. "I look forward to joining the amp team in order to advance the development of new high-quality therapies for patients in both the pharmerging and the regulated markets, the primary focus of the work at amp." Founding CEO Dr. Marc W. Hentz retires from the post in a planned succession move. "I am excited that we can implement our plan to attract an experienced industry leader to join amp for its next phase of corporate development. The Board's appointment of Klaus Wilgenbus is a testimony to our success and strategic direction, and I sincerely congratulate him. Klaus is an experienced biopharma executive and an outstanding dealmaker whose skill-set will directly contribute to the firm's future growth path. As a founder and shareholder I am excited about his future impact on the company and will continue to support amp in any advisory or other capacity required." Chairman of amp Supervisory Board Dr. Thomas Zimmer comments: "With Klaus Wilgenbus we have identified a leading pharma executive who brings a tremendous wealth of pharma and biotech knowhow to amp biosimilars AG. The addition of his business acumen enhances our ability to deliver high-value biosimilars for the future. I thank Marc Hentz for his 2 years of successful leadership in building the company and securing its first out licensing deals, and I am sure that Klaus Wilgenbus will ensure the continued expansion of our position as leader in biosimilar development." About amp biosimilars AG: amp biosimilars AG develops high quality biosimilars to meet growing demand on global therapeutic markets and is one of the most innovative and dynamic biosimilar companies in Europe. The company is headquartered in Hamburg and run by a team of leading industry experts. The development of a wide variety of biosimilars will provide patients around the world with access to life-improving and life-saving therapies. The combination of a research platform with state-of-the-art analytics, process technology and clinical expertise as well as regulatory know-how, makes amp biosimilars AG one of the leading companies for biosimilar development and marketing. Thanks to an international network of leading pharmaceutical companies, amp biosimilars AG also has direct access to the strongest growing markets in the world. With this approach amp biosimilars AG has a key position in one of the fastest growing life science markets in the near future. amp biosimilars AG has been listed on the Munich Stock Exchange since April 1, 2015. For more information please go to www.ampbiosimilars.com. Contact: Fabian Lorenz Florenz Kommunikation T: +49 211 29831588 E-mail: lorenz@florenz-kommunikation.de --------------------------------------------------------------------------- 28.06.2016 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de --------------------------------------------------------------------------- Language: English Company: amp biosimilars AG Am Kaiserkai 1 22391 Hamburg Germany Phone: +49 40 80 80 74 760 Internet: http://www.ampbiosimilars.com ISIN: DE000A0SMU87 WKN: A0SMU8 Listed: Regulated Unofficial Market in Munich End of News DGAP News Service --------------------------------------------------------------------------- 474787 28.06.2016

Die wichtigsten Finanzdaten auf einen Blick
  2013 2014 2015 2016 2017 2018 2019e 2020e
Umsatzerlöse1 0,00 0,00 0,00 0,00 0,05 2,55 10,00 125,00
EBITDA1,2 0,00 0,00 0,00 -1,03 -0,68 -4,94 -8,00 52,00
EBITDA-Marge3 0,00 0,00 0,00 0,00 -1.360,00 -193,73 -80,00 41,60
EBIT1,4 0,00 0,00 0,00 -1,03 -0,68 -5,57 0,00 0,00
EBIT-Marge5 0,00 0,00 0,00 0,00 -1.360,00 -218,43 0,00 0,00
Jahresüberschuss1 0,00 0,00 0,00 -1,04 -0,70 -5,60 0,00 0,00
Netto-Marge6 0,00 0,00 0,00 0,00 -1.400,00 -219,61 0,00 0,00
Cashflow1,7 0,00 0,00 0,00 -1,04 -0,69 -4,97 0,00 0,00
Ergebnis je Aktie8 0,00 0,00 0.00 -0,14 -0,09 -0,75 -0,30 0,40
Dividende8 0,00 0,00 0,00 0,00 0,00 0,00 0,00 0,00
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2018 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: AIOS

Northern Data
WKN Kurs in € Einschätzung Börsenwert in Mio. €
A0SMU8 55,600 Kaufen 663,34
KGV 2021e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
85,54 0,00 0,000 -463,33
-922,59 - 66,33 -83,304
Dividende '19 in € Dividende '20e in € Div.-Rendite '19e
in %
0,00 0,00 0,00 30.08.2019
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
26.09.2019 Juni 2020
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
29,42% 105,39% 175,25% 178,00%
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu amp biosimilars AG  ISIN: DE000A0SMU87 können Sie bei DGAP abrufen

IT-Infrastruktur , A0SMU8 , NB2 , XETR:NB2